Browse > Article
http://dx.doi.org/10.3857/roj.2017.00451

Treatment results of radiotherapy following CHOP or R-CHOP in limited-stage head-and-neck diffuse large B-cell lymphoma: a single institutional experience  

Jeong, Jae-Uk (Department of Radiation Oncology, Chonnam National University Hwasun Hospital)
Chung, Woong-Ki (Department of Radiation Oncology, Chonnam National University Hwasun Hospital)
Nam, Taek-Keun (Department of Radiation Oncology, Chonnam National University Hwasun Hospital)
Yang, Deok-Hwan (Department of Hematology-Oncology, Chonnam National University Hwasun Hospital)
Ahn, Sung-Ja (Department of Radiation Oncology, Chonnam National University Hwasun Hospital)
Song, Ju-Young (Department of Radiation Oncology, Chonnam National University Hwasun Hospital)
Yoon, Mee Sun (Department of Radiation Oncology, Chonnam National University Hwasun Hospital)
Kim, Yong-Hyeob (Department of Radiation Oncology, Chonnam National University Hwasun Hospital)
Publication Information
Radiation Oncology Journal / v.35, no.4, 2017 , pp. 317-324 More about this Journal
Abstract
Purpose: This study evaluated outcomes of radiotherapy (RT) after chemotherapy in limited-stage head-and-neck diffuse large B-cell lymphoma (DLBCL). Materials and Methods: Eighty patients who were treated for limited-stage head-and-neck DLBCL with CHOP (n = 43) or R-CHOP (n = 37), were analyzed. After chemotherapy, RT was administered to the extended field (n = 60) or the involved field (n = 16), or the involved site (n = 4). The median dose of RT ranged from 36 Gy in case of those with a complete response, to 45-60 Gy in those with a partial response. Results: In all patients, the 5-year overall survival (OS) and disease-free survival (DFS) rates were 83.9% and 80.1%, respectively. In comparison with the CHOP regimen, the R-CHOP regimen showed a better 5-year DFS (86.5% vs. 73.9%, p = 0.027) and a lower rate of treatment failures (25.6% vs. 8.1%, p = 0.040). The volume (p = 0.047) and dose of RT (p < 0.001) were significantly reduced in patients treated with R-CHOP compared to that in those treated with CHOP. Conclusion: The outcomes of RT after chemotherapy with R-CHOP were better than those of CHOP regimen for limited-stage head-and-neck DLBCL. In patients treated with R-CHOP, a reduced RT dose and volume might be feasible without increasing treatment failures.
Keywords
Diffuse large B-cell lymphoma; Radiotherapy; Antineoplastic agents; Head and neck neoplasms;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Jung KW, Won YJ, Kong HJ, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2012. Cancer Res Treat 2015;47:127-41.   DOI
2 Yu JI, Nam H, Ahn YC, Kim WS, Park K, Kim SJ. Involved-lesion radiation therapy after chemotherapy in limited-stage headand-neck diffuse large B cell lymphoma. Int J Radiat Oncol Biol Phys 2010;78:507-12.   DOI
3 Campbell BA, Connors JM, Gascoyne RD, Morris WJ, Pickles T, Sehn LH. Limited-stage diffuse large B-cell lymphoma treated with abbreviated systemic therapy and consolidation radiotherapy: involved-field versus involved-node radiotherapy. Cancer 2012;118:4156-65.   DOI
4 Krol AD, Berenschot HW, Doekharan D, Henzen-Logmans S, van der Holt B, van 't Veer MB. Cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy and radiotherapy for stage I intermediate or high grade non-Hodgkin's lymphomas: results of a strategy that adapts radiotherapy dose to the response after chemotherapy. Radiother Oncol 2001;58:251-5.   DOI
5 Lowry L, Smith P, Qian W, et al. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiother Oncol 2011;100:86-92.   DOI
6 Yahalom J, Illidge T, Specht L, et al. Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys 2015;92:11-31.   DOI
7 Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005;23:4117-26.   DOI
8 Rosenberg SA. Validity of the Ann Arbor staging classification for the non-Hodgkin's lymphomas. Cancer Treat Rep 1977;61:1023-7.
9 Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-Bcell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379-91.   DOI
10 Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008;9:105-16.   DOI
11 Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-86.   DOI
12 Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med 1998;339:21-6.   DOI
13 Nathu RM, Mendenhall NP, Almasri NM, Lynch JW. Non-Hodgkin's lymphoma of the head and neck: a 30-year experience at the University of Florida. Head Neck 1999;21:247-54.   DOI
14 Horning SJ, Weller E, Kim K, et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol 2004;22:3032-8.   DOI
15 Phan J, Mazloom A, Medeiros LJ, et al. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. J Clin Oncol 2010;28:4170-6.   DOI
16 Kwon J, Kim IH, Kim BH, Kim TM, Heo DS. Additional survival benefit of involved-lesion radiation therapy after R-CHOP chemotherapy in limited stage diffuse large B-cell lymphoma. Int J Radiat Oncol Biol Phys 2015;92:91-8.   DOI
17 National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology [Internet]. Fort Washington, PA: National Comprehensive Cancer Network; c2011 [cited 2017 Nov 27]. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp/PDF/b-cell.pdf
18 Kaplan HS. Hodgkin's disease: unfolding concepts concerning its nature, management and prognosis. Cancer 1980;45:2439-74.   DOI
19 Verhappen MH, Poortmans PM, Raaijmakers E, Raemaekers JM. Reduction of the treated volume to involved node radiation therapy as part of combined modality treatment for early stage aggressive non-Hodgkin's lymphoma. Radiother Oncol 2013;109:133-9.   DOI
20 Wilder RB, Tucker SL, Ha CS, et al. Dose-response analysis for radiotherapy delivered to patients with intermediategrade and large-cell immunoblastic lymphomas that have completely responded to CHOP-based induction chemotherapy. Int J Radiat Oncol Biol Phys 2001;49:17-22.   DOI